Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway

Nature Medicine

Volumn 6, Issue 3, 2000, Pages 283-289

  Tamada, Koji ^a   Shimozaki, Koji ^b   Chapoval, Andrei I ^a   Zhu, Gefeng ^a   Sica, Gabriel ^a   Flies, Dallas ^a   Boone, Tom ^c   Hsu, Hailing ^c   Fu, Yang Xin ^d   Nagata, Shigekazu ^b   Ni, Jian ^e   Chen, Lieping ^a  

^a MAYO CLINIC   (United States)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c AMGEN INC   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; CD28 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD18; CELL LINE; CLONING, MOLECULAR; GRAFT VS HOST DISEASE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; MEMBRANE PROTEINS; MICE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0034117337     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/73136     Document Type: Article

References (33)

1. Schwartz, R.H. Costimulalion of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065-1068 (1992).
2. Cross, A.H. et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95, 2783-2789 (1995).
3. Lenschow, D.J. et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257, 789-792 (1992).
4. Blazar, B.R., Taylor, P.A., Linsley, P.S. & Vallera, D.A. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-lg reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83, 3815-3825 (1994).
5. Chen, L. et al. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102 (1992).
6. Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Med. 3, 682-685 (1997).
7. Mauri, D.N. et al. LIGHT, a new member of the TNF superfamily, and lymphotoxic α are ligands for herpesvirus entry mediator. Immunity 8, 21-30 (1998).
8. Zhai, Y. et al. LIGHT, a novel ligand for lymphotoxin β receptor and TR2/H V E M induces apoptosis and suppresses in vivo tumor formation via gene transfer. J. Clin. Invest. 102, 1142-1151 (1998).
9. Harrop, J.A. et al. Antibodies to TR2 (Herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J. Immunol. 161, 1786-1794 (1998).
10. Kwon, B.S. et al. A new identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Bio. Chem. 272, 14272-14276 (1997).
11. Browning, J.L. et al. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J. Immunol. 159, 3288-3298 (1997).
12. Montgomery, R.I. et al., Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87, 427-436 (1996).
13. Smith, C.A., Farrah, T. & Goodwin, R.C. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959-962 (1994).
14. Yu, K.Y. et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274, 13733-13736 (1999).
15. Harrop, J.A. et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J. Biol. Chem. 273, 27548-27556 (1998).
16. Hsu, H. et al. ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5. J. Biol. Chem. 272, 13471-13474 (1997).
17. Marsters, S.A. et al. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κB and AP-1. J. Biol. Chem. 272, 14029-14032 (1997).
18. Chen, L. et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179, 523-532 (1994).
19. Via, C.S., & Shearer, G.M. T-cell interactions in autoimmunity: insights from a murine model of graft-versus-host disease. Immunol. Today 9, 207-213 (1988).
20. Ware, C.F. et al. The ligands and receptors of the lymphotoxin system. Curr. Top. Microbiol. Immunol. 198, 175-218 (1995).
21. Watts, T.H. & DeBenedette, M.A. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11, 286-293 (1999).
22. Pitti, R.M. et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699-703 (1998).
23. Force, W.R. et al. Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression. J. Immunol. 155, 5280-5288 (1995).
24. Degli-Esposti, M.A. et al. Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. J. Immunol. 158, 1756-1762 (1997).
25. Browning, J.L. et al. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J. Exp. Med. 183, 867-878 (1996).
26. Chaplin, D.D. & Fu, Y. Cytokine regulation of secondary lymphoid organ development. Curr. Opin. Immunol. 10, 289-297 (1998).
27. Mackay, F. & Browning, J.L. Turning off follicular dendritic cells. Nature 395, 26-27 (1998).
28. Speiser, D.E. et al. TNF receptor p55 controls early acute graft-versus-host disease. J. Immunol. 158, 5185-5190 (1997).
29. De Togni, P. et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264, 703-707 (1994).
30. Banner, D.W. et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF β complex: Implications for TNF receptor activation. Cell 73, 431-445 (1993).
31. Karpusas, M. et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure 3, 1031-1039 (1995).
32. Cha, SS. et al. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective anti-tumor activity. Immunity 11, 253-261 (1999).
33. Johnson, A.J. et al. Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor-α, gamma interferon, perforin, or costimulation through CD28. J. Virol. 73, 3702-3708 (1999).